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Retinal dystrophy (RD) is a heterogeneous group of hereditary diseases caused by loss of photoreceptor function and
contributes significantly to the etiology of blindness globally but especially in the industrialized world. The extreme locus
and allelic heterogeneity of these disorders poses a major diagnostic challenge and often impedes the ability to provide
a molecular diagnosis that can inform counseling and gene-specific treatment strategies. In a large cohort of nearly 150 RD
families, we used genomic approaches in the form of autozygome-guided mutation analysis and exome sequencing to
identify the likely causative genetic lesion in the majority of cases. Additionally, our study revealed six novel candidate
disease genes (C21orf2, EMC1, KIAA1549, GPR125, ACBD5, and DTHD1), two of which (ACBD5 and DTHD1) were observed in the
context of syndromic forms of RD that are described for the first time.
[Supplemental material is available for this article.]
Deprivation of visual perception is a major form of morbidity
worldwide with a wide array of causes that cover the entire spectrum
from primarily environmental to primarily genetic. Representing
the Mendelian end of the spectrum, retinal dystrophy (RD) is a vast
group of blinding diseases that are characterized by loss of photore-
ceptor function, usually due to mono- or biallelic mutations in an
expansive list of genes (Wright et al. 2010). Collectively, RD is amajor
cause of blindness, particularly in industrialized countries where in-
fectious causes are less common and where treatable blinding dis-
eases such as cataract and glaucoma receive adequate management.
Clinically, RD can take various forms, retinitis pigmentosa
(RP) being the most common (Buch et al. 2004). RP patients typ-
ically present with a predominantly rod dysfunction, which
manifests as night blindness, progressively worsening peripheral
vision, and typical fundus appearance (Ho 2003; Hamel 2006). In
cone dystrophies, it is the cone photoreceptors that are primarily
involved, causing a substantial decrease in visual acuity and pho-
tophobia (Hamel 2007). In both classes, the other photoreceptor
subtype is inevitably affected as the disease progresses, hence the
terms rod-cone and cone-rod dystrophy, although the mechanism
for this sympathetic cell loss is poorly understood. When severe
RD is congenital or early-infantile in onset, it is usually referred to
as Leber congenital amaurosis (LCA). Interestingly, the clinical
boundaries between these subclasses are blurred by the increasing
appreciation of the marked phenotypic variability that is associated
with mutations in a large number of RD genes (Daiger et al. 2007).
The remarkable genetic heterogeneity (179 genes as of January
2012; https://sph.uth.tmc.edu/Retnet/sum-dis.htm) and the poor
predictive value of the clinical assessment to the specific genetic
etiology (at least in nonsyndromic cases) make it extremely chal-
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lenging to offer a molecular diagnosis to these patients (Koenekoop
et al. 2007). Thus, of all Mendelian disorders, this is one disease
category where most patients remain unaware of their underlying
causative mutation even though such information is critical for
informed genetic counseling that aims at prevention and expan-
sion of available reproductive options. This is compounded by
estimates that, even if all known RD were to be sequenced in a
given patient, the yield is probably 50% (Farrar et al. 2002; Hartong
et al. 2006; den Hollander et al. 2008). An additional value in se-
curing a molecular diagnosis lies in the recent progress in gene
therapy, which has prompted many RD patients to seek to de-
termine their mutation status in order to know whether they are
eligible for these gene-specific treatment protocols (Maguire et al.
2008). In addition, certain classes of mutations have been found to
be amenable to treatment in other diseases, e.g., nonsense muta-
tions, which offers hope that RD patients with such mutations
could similarly benefit from such innovative strategies, but this
will require prior knowledge of the underlying genetic defect
(Kerem et al. 2008).
Research in the genetics of RD has greatly improved our un-
derstanding of the molecular machinery that enables the retina to
play a critical role in the perception of visual stimuli (Inglehearn
1998). While some of the genes were predicted to cause RD based
on established physiological roles of the protein they encode, e.g.,
phototransduction genes, it came as a surprise that almost one in
four RD genes plays a role in the photoreceptor cilium (Adams et al.
2007; Wright et al. 2010). Moreover, many genes were completely
unsuspected, e.g., pre-mRNA splicing genes, and the function of
some remains unknown (Vithana et al. 2001; Faustino and Cooper
2003; Wright et al. 2010). Indeed, the increasing pace of discovery
of RD genes over the past few years has widened the gap between
our knowledge of the genetic architecture of RD and its functional
context.
In this study, we aimed to investigate the utility of genomic
approaches in the study of RD genetics. Specifically, we imple-
mented autozygome analysis (Woods et al. 2006; Alkuraya 2010)
and exome sequencing in a large cohort of simplex and multiplex
patients with different clinical RD subtypes. In addition to pro-
viding the most comprehensive analysis to date on the actual
contribution of known RD genes to the overall mutation pool, our
study reveals six novel RD genes, including two involved in novel
syndromic forms of RD, and suggests a framework for mutation
identification in these patients.
Results
Clinical characteristics
For the period January 2008–September 2010, 149 eligible families
were enrolled representing the threemajor clinical subtypes of RD,
i.e., RP, LCA, and cone-rod dystrophy, but other less common
phenotypes such as achromatopsia were also represented. With
the exception of cone-dystrophy with supranormal rod response
patients in whom KCNV2 was directly sequenced, it was not pos-
sible to predict the genetic defect based on the phenotype pro-
vided, and they were processed as per the workflow outlined in
Figure 1. Workflow of the study.
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Figure 1. As expected, RP accounted for the majority of patients
(;55%). Themajority of casesweremultiplex (60%), and therewas
remarkable clinical homogeneity among affected members of
a given family. Family arRP-FD02 (Supplemental Fig. S1) is worth
highlighting in this regard. In this family of four affectedmembers
with RP (two siblings on either side of a first cousin relationship),
two siblings on one side had additional features of Bardet-Bied
syndrome (BBS). Although the two siblings in the other branch
lacked any additional BBS feature, one of these two siblings had an
infant with BBS in the course of the study. As a result, and based on
our experience of rare cases inwhich BBS presents as nonsyndromic
RP (Abu Safieh et al. 2010, 2012), we enrolled this family in this
study. However, autozygome analysis and exome sequencing con-
firmed that the apparent clinical heterogeneity in this familywas, in
fact, the result of independent segregation of two different diseases:
RP secondary to RP1 mutation and BBS due to BBS1 mutation. In
Family arRP-F026, which was enrolled as nonsyndromic RP, the
finding of a BBS4 mutation prompted us to recall the family for
careful phenotyping, and the result indicated that the phenotype
should have been labeled as BBS. On the other hand, Family CR-
F008, in which we identified a novel MKS1 mutation, was found
upon rephenotyping to have no syndromic features. Thus, this
appears to be the first report of MKS1 mutation causing non-
syndromic cone-rod dystrophy.
Autozygome-guided gene sequencing
This was pursued in both simplex and multiplex cases because of
our past experience of the very high rate of homozygousmutations
even in the absence of consanguinity or positive family history
(Aldahmesh et al. 2009). The yield was only slightly lower in
simplex compared with multiplex cases (42% vs. 52%) (Fig. 2).
On average, four genes were sequenced per case (range 1–11).
The average number of amplicons per case was 200, with an
average cost of $3000. The results of autozygome-guided tar-
geted RD gene sequencing are summarized in Table 1 and Sup-
plemental Table S1 (solved cases) and Supplemental Table S4
(unsolved cases).
Exome sequencing for mutation detection in RD
The first group of exomes comprised randomly selected 10 simplex
and 23 multiplex cases to investigate the yield of this method in
sporadic and familial cases of this extremely heterogeneous dis-
order. Of the 10 simplex cases, eight (80%) were found to harbor
pathogenic mutations in known RD genes. A similar ratio (17/23,
74%) was observed inmultiplex cases (Fig. 2). In all these cases, the
pathogenic mutation was always homozygous (Table 2; Supple-
mental Table S2). By checking these mutations against the auto-
zygome data we had prepared for this purpose, it was clear that all
these changes could have been identified by autozygome-guided
targeted RD gene sequencing because they either resided within
one of the largest four runs of homozygosity (ROH) (in simplex
cases) (Supplemental Table S5) or an ROH that was exclusively
shared by the affected members of a given family (in multiplex
cases). However, there is a significant time and money difference
in favor of exome sequencing. Indeed, a typical turnaround time
for identifying the causative mutation by exome was 8 wk com-
pared to 15 wk for autozygome-guided analysis. The cost of $1500
per exomewas also lower than the $3000 per case solved using the
autozygome-guided approach. Furthermore, exome sequencing
revealed mutations in two multiplex cases that were missed by
the autozygome-guided approach because these mutations were
in homozygous regions which were shared with an unaffected in-
dividual, yet the apparently shared ROH
was clearly IBS (identical-by-state) (Sup-
plemental Fig. S2).
Exome as a discovery tool for novel
RD genes
The first group of exomes (see above) also
revealed two novel candidate genes for
RD (Tables 3, 4). In Family sRP-001 (mul-
tiplex), a truncatingmutation in LGALS9B
encoding Galectin-9B protein A2 and
a missense mutation in EMC1 were the
only variants that survived filtration
(Table 3; Supplemental Table S3; Supple-
mental Fig. S4). However, direct full se-
quencing of both genes in the 11 patients,
out of 210 total RD patients in the repli-
cation cohort, whose autozygome over-
lapped with at least one of the two genes
revealed one patient who is homozygous
for the same mutation in EMC1 but no ad-
ditional alleles of LGALS9B. Importantly,
the same LGALS9B truncation was later
found at high frequency on direct se-
quencing of additional ethnicallymatched
controls. On the other hand, the novel
EMC1 variant was absent from 380 Saudi
controls by direct sequencing and in
the Exome Variant Server and is highly
Figure 2. Central pie chart summarizes the contribution of various genes to the overall mutational
pool among RD patients in the current study. Pie charts in the upper panel show the percentage of
mutation-positive cases among simplex and multiplex cases using the autozygome-guided gene se-
quencing approach. Pie charts in the lower panel show the percentage of mutation-positive cases
among simplex and multiplex cases using the exome sequencing approach. Please note the percent-
ages in these charts do not take into account the novel candidate genes identified in this study.
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conserved across species. Taken together, these data strongly sup-
port the candidacy of EMC1 in the pathogenicity of RP in the two
individuals who are homozygous for that variant, although very
little is known about this gene. In Family CR-F024 (simplex),
a truncating mutation in the hypothetical protein coding gene
C21orf2 was the only variant that survived the various filters. As
with the EMC1, thiswas absent in 160 Saudis by exome sequencing
and in 190 Saudi controls by direct sequencing and in the Exome
Variant Server (EVS). More importantly, by direct sequencing in
the seven individuals in the replication cohort whose autozygome
pattern overlapped with this gene, one patient was found to be ho-
mozygous for a splicing mutation (NM_004928.2:c.545 + 1G>A) that
fully abolishes the donor site in silico, whichwas absent in the panels
of controls described above. Thus, C21orf2 is a compelling can-
didate in the pathogenesis of cone-rod dystrophy in these two
individuals.
The second group of exomes (n = 12) was enriched for novel
gene discovery because all known RD genes had been excluded in
these multiplex families by the autozygome-guided sequencing
approach. As mentioned above, despite this enrichment, 3/12
harbored mutations in known RD genes that were missed for var-
ious reasons (two because of IBS [identical by state] being confused
with IBD [identical by descent], and one because of a highly un-
usual pedigree structure; see Supplemental Figs. S1, S2). A novel
candidate gene was identified in each of four additional families
(Tables 3, 4). In Family sRP-022 (multiplex), a novel missense
mutation was identified in an absolutely conserved residue of the
sixth transmembrane helix of G protein-coupled receptor 125
(GPR125). Of note, mutations in several other G protein-coupled
receptors are known to cause RD (Dryja et al. 1990;Morimura et al.
1999; Ebermann et al. 2009; Hilgert et al. 2009). In Family sRP-004
(multiplex), a novel truncating variant was identified in KIAA1549
as the only variant that remained after applying the various filters.
Virtually nothing is known about this hypothetical protein-coding
gene. However, it is among the top 4% of genes enriched for CRX-
binding sites in a data set used to identify MAK as a novel RD gene
(Ozgul et al. 2011; Tucker et al. 2011). Additionally, while the re-
duction of MAK representation in retina of mice with loss of
photoreceptors was ;26%, that of KIAA1549 was ;88%, suggest-
ing specific loss of this gene in photoreceptor degeneration (Ozgul
et al. 2011). As with the GPR125 variant, this truncating variant
was not encountered in any of 160 Saudi exomes or 190 Saudi
controls by direct sequencing. Both were also absent in the EVS.
These data support the candidacy of these two genes as novel RD
genes. However, direct sequencing of both in the 27 patients in the
replication cohort whose autozygome overlapped with either of
these two genes revealed no additional mutations.
Two families displayed an apparently novel syndromic form
of RD. In Family LCA-F045, LCA segregated with a mild-moderate
form of nonspecific muscle dystrophy. By only considering the
exome variants within the three exclusively shared ROH among
the affected members, we uncovered a single nucleotide sub-
stitution that abolishes the first methionine residue of DTHD1
encoding death domain-containing protein 1 (Supplemental Fig.
S3).Western blot analysis showed a greater than fourfold reduction
in the abundance of the mutant protein compared to control (Fig.
3). Virtually nothing is known about this hypothetical protein
other than that it contains a death domain. However, the identi-
fication of this as the only variant within the shared ROH, its effect
on the protein, its full segregation with the phenotype in this ex-
tended family, and its absence in a large number of controls
strongly support its candidacy as the causal gene for this appar-
ently novel LCA/muscular dystrophy syndrome. In Family
CRSPW, an apparently novel association between cone-rod dys-
trophy and psychomotor delay associated with significant white
matter involvement was observed. A single novel variant was
identified in the single ROH that is exclusively shared by the three
affected siblings (Supplemental Fig. S3). The variant is predicted to
abolish a consensus splice donor site in ACBD5. Indeed, RT-PCR
confirmed the resulting aberrant transcript that predicts frameshift
and premature truncation. However, despite lack of evidence of
nonsense-mediated decay (NMD), Western blot analysis showed
no evidence of the expected smaller band as a result of the trun-
cation (the normal band was completely absent), even though the
antibody targets the N terminus part of the protein (Fig. 3). Thus, it
appears that the mutation causes severe instability of the protein
and can be considered as a null allele. Reassuringly, as with the
DTHD1 variant, this variant was absent in 160 Saudi exomes, 190
Saudi controls by direct sequencing, and EVS. ACBD5 encodes
acyl-coenzyme A binding domain-containing protein 5, so it re-
mains to be seen, as is the case with the above-mentioned novel
candidates, how deficiency of this protein may have caused this
phenotype.
In the remaining five families, no novel variants were iden-
tified after applying the various filters. Interestingly, linkage
analysis in four of these families showed one single peak each
(Chr17: 3,745,860-7,201,753 in LCA-F037, Chr3: 83,157,375-
107,875,119 in arRP-F048, Chr8: 75,000,000-110,000,000 in arRP-
F074, and Chr7:105,000,000-147,000,000 in arRP-F077) (Supple-
mental Table S6). In the remaining one family, we could not nar-
row the search to a single locus, so several ROHs were used in the
filtration of the data.
Discussion
The extreme genetic heterogeneity of RD and the often poor pre-
dictive power of clinical assessment in determining the underlying
genetic defect have severely hampered the ability of these patients
to receive specific genetic diagnosis that can be the basis of in-
formed genetic counseling and gene-specific therapy (Berger et al.
2010; den Hollander et al. 2010). Some attempts have been made
Figure 3. Western blot analysis of DTHD1 and ACBD5 in two families
representing novel syndromic forms of RD. Fourfold reduction in the
DTHD1 intensity in the patients compared to control and near-absence of
the band corresponding to ACBD5 among patients can be seen. GAPDH
is used for a loading control.
Autozygome/exome analysis in retinal dystrophy
Genome Research 243
www.genome.org
 Cold Spring Harbor Laboratory Press on February 28, 2014 - Published by genome.cshlp.orgDownloaded from 
to reduce this diagnostic challenge. In one approach, all previously
reported mutations in RD genes were captured on a genotyping
chip (Koenekoop et al. 2007). Unfortunately, the extreme allelic
heterogeneity limits the usefulness of this method. The rese-
quencing chip theoretically circumvents this limitation, but the
prerequisite step of amplifying all known RD genes represents
a major challenge (Booij et al. 2011). We and others have shown
that the autozygome approach can be very effective in guiding the
mutation analysis (Aldahmesh et al. 2009; Pomares et al. 2010).
Interestingly, this approach was also used successfully in pop-
ulations where consanguinity is uncommon (Hildebrandt et al.
2009; Collin et al. 2011; Hagiwara et al. 2011; Schuurs-Hoeijmakers
et al. 2011). However, this approach has its limitations. Only
homoallelic mutations are identified by this method, so compound
heterozygosity for recessive RD genes, heterozygosity for dominant
RD genes, andhemizygosity for X-linked RDgenes aremissed.More
importantly, novel genes can only be identified in favorable pedi-
grees, i.e., those in which enough crossing-overs reduce the haplo-
type sharing to a level that allows a relatively small ROH to be
identified that is exclusively shared by the affected members. In-
deed, lining up the autozygome pattern of unrelated individuals,
which has been used to identify disease loci for autosomal recessive
traits in the past as a way to circumvent the limited informativeness
of any given family, is largely inapplicable, given the remarkable
locus heterogeneity of RD. Finally, as we show in this study, the
distinction of IBS and IBD can be challenging (Alkuraya 2012).
Next-generation sequencing allows massively parallel se-
quencing at an unprecedented scale both in throughput and cost
and has recently been used on a smaller scale in the study of retinal
dystrophy genetics (Audo et al. 2012; Neveling et al. 2012). Exome
sequencing is one of its applications where the protein-coding
exons of all known genes can be captured, followed by high-
throughput sequencing. Although deep intronic and noncoding
regulatory sequencemutations are not covered by thismethod, we
hypothesized that it still lends itself as a powerful genomic tool to
at once identify mutations in known RD genes and identify novel
RD genes, and we set out to investigate its utility both in isolation
and in combination with the autozygome approach.
Our data show autozygome-guided sequence analysis of
known RD genes is applicable to bothmultiplex and simplex cases,
which suggests that, even in simplex cases, autosomal recessive RD
is the commonest form, at least in our population that is charac-
terized by a high rate of consanguinity. Although a few founder
mutations were identified, we find that, similar to our experience
with other genetically heterogeneous conditions, there is marked
allelic and locus heterogeneity in our population, even within the
same tribe. However, we caution against the overinterpretation of
this phenomenon as being indicative of high population genetic
diversity akin to what is observed in Africa, without empirical
population genetic data, which still do not exist for Arabia.
An important yet largely unanswered question is how much
the current list of RD genes contributes to the overall genetic ar-
chitecture of this disease. Only estimates are available because,
until recently, the onlyway to empirically test this was through the
PCR amplification of all RD genes, an extremely challenging task.
By performing exome sequencing on randomly selected multiplex
and simplex cases, we were able to show that the genes identified
as of January 2012 account for 74%–80% of the overall mutation
pool in our population. Interestingly, all mutations identified by
exome sequencing of simplex cases were homoallelic even though
hemizygous X-linked, and compound heterozygous mutations in
all knownRD geneswere equally likely to be identified. Indeed, the
comparable yield of unselected exomes in simplex and multiplex
cases argues against a major contribution of X-linked RD genes in
simplex cases in our population. It is unclear how applicable this
result is to more outbred populations, although evidence suggests
that many sporadic patients in those populations also represent
autosomal recessive inheritance (Avila-Fernandez et al. 2010;
Iwanami et al. 2012). Another important result from our study is
that our exome sequencing data make it unlikely that any addi-
tional novel gene will account for a substantial fraction of the
remaining cases (see below).
As predicted, in addition to revealingmostmutations in known
RD genes, exome sequencing was a useful discovery tool as well. We
and others have previously demonstrated the power of exome se-
quencing in revealing novel disease genes based on simplex cases
(Gilissen et al. 2010; Aldahmesh et al. 2011; Shaheen et al. 2011).
Our data expand the disease phenotypes for which simplex cases
can be used to identify novel disease genes to also include RD. Un-
fortunately, the very low contribution of most RD genes to the
overall mutation pool makes it challenging to identify additional
pathogenic alleles in the candidate genes we identified in this study,
so they remain interesting candidates pending independent verifi-
cation by future studies (at least in the four for which no additional
mutation-positive patientswere identified in the replication cohort).
Many syndromes are known to involve the RD phenotype
(Ayuso et al. 1995). However, we are not aware of any previously
described association between LCA and muscular dystrophy or
between cone-dystrophy and severewhitematter disease. Thus, we
believe these are two novel syndromic forms of RD. In both fam-
ilies, compelling loss of function alleles were identified (DTHD1
and ACBD5), but additional work is needed to explore the pre-
sumed causal link mechanistically. These families were part of
a collection we tried to enrich for novel RD genes. However, we
show how pitfalls in homozygosity scan caused false negative re-
sults in three of the 11 families. In fact, the 13.3-Mb IBS that caused
confusion in the analysis of Family arRP-F069 is the largest IBS that
we are aware of (Supplemental Fig. S2; Alkuraya 2012). Thus, it is
possible that the higher yield of exome compared to autozygome-
guided analysis can be, at least in part, caused by occasional pitfalls
in homozygosity scan. Overall, we show that exome sequencing
was superior to the autozygome-guided approach, and although
the latter can be very helpful in lending credence to novel disease
genes, it does not appear necessary in interpreting exome variants
in known RD genes.
In summary, in this largest comprehensive genomic study of
RD patients to date, we show that genomic tools are very useful in
identifying the underlying genetic lesion. Exome sequencing in
particular appears to be an attractive first-line test without prior
enrichment for known RD genes, especially with its constantly
decreasing cost. The novel disease genes we identified require
validation in independent patient cohorts. Similar studies on
outbred populations will be needed to explore potential differ-
ences in the genetic architecture of RD compared to what we
presented in this study.
Methods
Human subjects
Patients with RP, LCA, and cone-rod dystrophy were actively
recruited regardless of their age or family history through a wide
network of ophthalmologists that covers all regions of Saudi Arabia
for the period January 2008 to September 2010. Patients recruited
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between September 2010 and May 2012 were only used as a ‘‘rep-
lication cohort’’ for the purpose of identifying additional muta-
tions in the novel candidate genes we may identify in the main
cohort. Assignment to a specific clinical subtype was based on
clinical and, in selected cases, electrophysiological assessment.
Syndromic patients were only considered further if they did not fit
the clinical description of a known syndrome, e.g., Usher, Bardet-
Biedl, Alstrom, and Joubert syndrome (these patients were
recruited for other projects). Pedigrees were drawn for all recruited
patients, and an effort was made to enroll additional affected rel-
atives when present. Whenever possible, we enrolled parents and
unaffected siblings for segregation analysis. All subjects signed an
IRB-approved written informed consent (RAC# 2070 023), fol-
lowed by venous blood sampling in EDTA tubes. For selected pa-
tients, we also obtained blood samples in sodium heparin tubes
followed by establishment of EBV-transformed lymphoblast cell
lines for RNA and protein studies.
Workflow
Figure 1 summarizes the algorithm we implemented in the study
which is described below in detail.
Autozygome analysis
Genotyping was performed on an Affymetrix Axiom or Affymetrix
250K SNP chip platform following the manufacturer’s instructions
on the index only (in simplex cases) and the entire sibship, when
possible (in multiplex cases). Autozygome analysis was performed
using Genotyping Console (Affymetrix) or autoSNPa as described
before (Carr et al. 2006). In simplex cases, we only considered the
four largest runs of homozygosity (ROH) initially, but if negative,
we expanded our search to all ROHs that are >2 Mb in size. In
multiplex cases, we considered all ROHs that are exclusively shared
by the affectedmembers of a given sibship. All RD genes within an
ROHwere sequenced evenwhen they appeared incompatible with
the specific phenotype or pattern of inheritance to account for the
known phenotypic variability of mutations in RD genes and the
dual inheritance pattern for some of them. Twelve out of 30 mul-
tiplex cases in which autozygome-guided targeted RD gene se-
quencing failed to identify the causative mutation were processed
for exome sequencing.
Exome sequencing and analysis
Two groups of samples were processed for exome sequencing. The
first group represents randomly selected simplex (10) and multi-
plex (23) cases. The second group represents samples in which
autozygome-guided targeted RD gene sequencing failed to identify
the causative mutation by the first freeze point (12 out of 30) (Fig.
1). The aim of the first groupwas to investigate the utility of exome
sequencing as a first-pass diagnostic test in RD, whereas the aim
was to enrich for novel RD genes in the second group. Exome
capture was performed using the TruSeq Exome Enrichment kit
(Illumina) following the manufacturer’s protocol. Samples were
prepared as an Illumina sequencing library, and in the second step,
the sequencing libraries were enriched for the desired target using
the Illumina Exome Enrichment protocol. The captured libraries
were sequenced using an IlluminaHiSeq2000 Sequencer. The reads
were mapped against UCSC hg19 (http://genome.ucsc.edu/) by
BWA (http://bio-bwa.sourceforge.net/). The SNPs and indels were
detected by SAMtools (http://samtools.sourceforge.net/). For sub-
sequent analysis, we always started by checking all genes reported
to cause RD until January 2012. We considered homozygous,
heterozygous, hemizygous, and compound heterozygous changes
in these genes that are likely to be pathogenic, i.e., coding (ex-
cluding synonymous unless they affect splice site) or splice-site
variants that are not present in 160 in-house Saudi exomes. It is
important to mention that we manually checked all dbSNP vari-
ants in these genes against the Human Genome Mutation Data-
base since a lot of previously reported pathogenic mutations are
listed in dbSNP. Only when no such changes are identified did we
proceed with the analysis of sequence variants following the fil-
tration scheme outlined in Table 3 and Supplemental Figure S4.
The autozygome filter refers to variants present within the four
largest blocks of homozygosity in simplex cases and all blocks of
shared homozygosity in multiplex cases.
Replication analysis of novel candidate genes
Novel candidate genes were fully sequenced in the ‘‘replication
cohort’’ in search of additional alleles using standard PCR and
Sanger sequencing. We specifically sequenced patients whose
autozygome overlapped with any of these novel candidates.
RT-PCR and immunoblotting
Splice-site mutations were checked for potential effect on splicing
in silico. Whenever possible, mutations that are likely to affect
splicing were verified on RT-PCR using custom-made primers and
lymphoblast-derived RNA as a template. Truncating mutations
in novel genes were verified whenever possible by Western blot
analysis using commercially available antibodies and lym-
phoblast-derived protein as the target and following standard
protocols.
Data access
All novel sequence variants in known RD genes as well as those in
the novel candidate genes that we report in this study have been
submitted to the LeidenOpenVariation Database (http://grenada.
lumc.nl/LOVD2/eye/variants.php) under the following IDs:
ABCA4_00014, ACBD5_00001, C21orf2_00001, C2orf71_00006,
CDHR1_00001, CERKL_00001, CNNM4_00001, CRB1_00038,
CRB1_00037, DTHD1_00001, EMC1_00001, EYS_00006, GPR125_
00001, KIAA1549_00001, LCA5_00001, PRPH2_00003, RDH12_
00002.
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